Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Heart Failure After Acute Myocardial Infarction
NCT06812546Phase 4Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (2 arms). Primary endpoint: Serum NT-proBNP Level at 24 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06812546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812546.